[1]张杰 蒋斌 裴斐① 张铃福 原春辉 凌晓锋** 修典荣**.基于倾向性评分匹配的腹腔镜与开腹手术治疗肝内胆管癌疗效的初步分析[J].中国微创外科杂志,2024,01(7):465-472.
　Zhang Jie*,Jiang Bin*,Pei Fei,et al.Effectiveness Analysis of Laparoscopic and Open Surgeries in the Treatment of Intrahepatic Cholangiocarcinoma: a Propensity Score Matching Study[J].Chinese Journal of Minimally Invasive Surgery,2024,01(7):465-472.
点击复制

基于倾向性评分匹配的腹腔镜与开腹手术治疗肝内胆管癌疗效的初步分析()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2024年7期
页码:
465-472
栏目:
临床论著
出版日期:
2024-08-25

文章信息/Info

Title:
Effectiveness Analysis of Laparoscopic and Open Surgeries in the Treatment of Intrahepatic Cholangiocarcinoma: a Propensity Score Matching Study
作者:
张杰 蒋斌 裴斐① 张铃福 原春辉 凌晓锋** 修典荣**
(北京大学第三医院普通外科，北京100191)
Author(s):
Zhang Jie*;  Jiang Bin*;  Pei Fei;  et al.
*Department of General Surgery, Peking University Third Hospital, Beijing 100191, China
关键词:
肝内胆管癌; 腹腔镜手术; 开腹手术
Keywords:
Intrahepatic cholangiocarcinoma; Laparoscopic surgery; Open surgery
文献标志码:
A
摘要:
目的初步分析腹腔镜手术与开腹手术治疗肝内胆管癌(intrahepatic cholangiocarcinoma, ICC)的疗效。方法回顾性分析我科2010年9月~2023年3月84例ICC接受手术治疗的临床资料，腹腔镜组45例，开腹组39例，通过倾向性评分匹配，最终34对数据成功匹配，比较2组手术时间、术中出血量、清扫≥6枚淋巴结比例、R0切除率、并发症、术后住院时间、生存率及复发等。结果腹腔镜组术中出血量明显少于开腹组(中位数: 250 ml vs. 750 ml, Z=-3.406,P=0.001)；腹腔镜组清扫≥6枚淋巴结比例与开腹组比较差异无统计学意义(5.9% vs. 17.6%, χ2=1.275,P=0.259)；腹腔镜组与开腹组R0切除率差异无显著性［88.2%(30/34) vs. 82.4%(28/34), χ2=0.469,P=0.493］。腹腔镜组总并发症发生率17.6%(6/34)，显著低于开腹组47.1%(16/34)(χ2=6.719,P=0.010)；2组严重并发症率均为2.9%(χ2=0.000,P=1.000)。腹腔镜组术后住院时间明显缩短(中位数: 7 d vs. 10 d, Z=-3.021,P=0.003)。腹腔镜组中位总生存期60.6月，明显长于开腹组15.9月(logrank χ2=5.788,P=0.016)；腹腔镜组中位无复发生存期26.4月，明显长于开腹组7.6月(logrank χ2=4.532,P=0.033)。结论腹腔镜肝切除术治疗ICC具有出血量少、并发症发生率低、术后住院时间短、生存期延长等优势，R0切除率、充分淋巴结清扫率与开腹手术相当。
Abstract:
ObjectiveTo preliminarily analyze the efficacy of laparoscopic surgery versus open surgery in patients with intrahepatic cholangiocarcinoma (ICC).MethodsA retrospective analysis was conducted on 84 patients with ICC who underwent surgical resection from September 2010 to March 2023, including 45 cases in the laparoscopic surgery group and 39 in the open surgery group. By using propensity score matching, 34 matched pairs were successfully identified. The study compared intraoperative blood loss, proportion of achieving ≥6 lymph nodes dissection, R0 resection rate,complication, postoperative hospital stay, survival, and recurrence between the two groups.ResultsIn the laparoscopic group, intraoperative blood loss was significantly less than that in the open surgery group (median: 250 ml vs. 750 ml, Z=-3.406, P=0.001). The proportion of achieving ≥6 lymph node dissection in the former was lower than that in the latter, but the difference was not statistically significant (5.9% vs. 17.6%, χ2=1275, P=0.259). There was no statistical difference in R0 resection rate between the laparoscopic group and the open surgery group ［88.2%(30/34) vs. 82.4%(28/34), χ2=0.469,P=0.493］.The complication rate in the laparoscopic group was 17.6%(6/34), significantly lower than 47.1%(16/34) in the open surgery group (χ2=6.719, P=0.010); however, the rate of severe complication was the same in both groups at 2.9% (χ2=0.000, P=1.000). Laparoscopic surgery significantly shortened the postoperative hospital stay (median: 7 d vs. 10 d, Z=-3.021, P=0.003). The median overall survival in the laparoscopic group was 60.6 months, significantly longer than 15.9 months in the open surgery group (logrank χ2=5788, P=0016). The median recurrencefree survival was 26.4 months in the laparoscopic group, significantly longer than 7.6 months in the open surgery group (logrank χ2=4532, P=0.033).ConclusionsCompared to open surgery, laparoscopic surgery for ICC offers advantages such as less blood loss, lower complication rate, shorter postoperative hospital stay and longer survival. It achieves comparable R0 resection rate and adequate lymph node dissection.

参考文献/References:

[1]Ramai D, Ofosu A, Lai JK, et al Combined hepatocellular cholangiocarcinoma: A populationbased retrospective study. Am J Gastroenterol,2019,114(9):1496-1501.
[2]编写专家委员会肝内胆管癌病理诊断专家共识版.肝内胆管癌病理诊断专家共识(2022版).中华病理学杂志,2022,51(9):819-827.
[3]Saha SK, Zhu AX, Fuchs CS, et al. Fortyyear trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. Oncologist,2016,21(5):594-599.
[4]Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep,2021,3(2):100226.
[5]Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part Ⅲ: Liver, biliary tract, and pancreas. Gastroenterology,2009,136(4):1134-1144.
[6]Konstantinidis IT, Groot Koerkamp B, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer,2016,122(5):758-765.
[7]Nakeeb A, Tran KQ, Black MJ, et al. Improved survival in resected biliary malignancies. Surgery,2002,132(4):555-564.
[8]Amini N, Ejaz A, Spolverato G, et al. Temporal trends in liverdirected therapy of patients with intrahepatic cholangiocarcinoma in the United States: a populationbased analysis. J Surg Oncol,2014,110(2):163-170.
[9]Mazzaferro V, Gorgen A, Roayaie S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol,2020,72(2):364-377.
[10]Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curativeintent surgical resection. Ann Surg Oncol,2016,23(1):235-243.
[11]Hoffmann K, Hinz U, Stravodimos C, et al. Risk assessment for liver resection. Surgery,2018,164(5):998-1005.
[12]中国抗癌协会肝癌专业委员会胆管癌协作组.原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版).中华消化外科杂志,2022,21(10):1269-1301.
[13]Benedetto U, Head SJ, Angelini GD, et al. Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg,2018,53(6):1112-1117.
[14]Yamamoto Y, Sugiura T, Okamura Y, et al. The evaluation of the eighth edition of the AJCC/UICC staging system for intrahepatic cholangiocarcinoma: a proposal of a modified new staging system. J Gastrointest Surg,2020,24(4):786-795.
[15]Wang J, Ma D, Du G, et al. Laparoscopic vs. open anatomical hepatectomy for intrahepatic cholangiocarcinoma:A retrospective cohort study. Front Surg,2022,9:1003948.
[16]Clavien PA, Barkun J, de Oliveira ML, et al. The ClavienDindo classification of surgical complications: fiveyear experience. Ann Surg,2009,250(2):187-196.
[17]Antwi SO, Mousa OY, Patel T. Racial, ethnic, and age disparities in incidence and survival of intrahepatic cholangiocarcinoma in the United States;1995-2014.Ann Hepatol,2018,17(4):604-614.
[18]Yao KJ, Jabbour S, Parekh N, et al. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. BMC Gastroenterol,2016,16(1):117.
[19]Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol,2019,71(1):104-114.
[20]Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg,2018,105(7):848-856.
[21]Cillo U, Fondevila C, Donadon M, et al. Surgery for cholangiocarcinoma. Liver Int,2019,39 Suppl 1(Suppl Suppl 1):143-155.
[22]Sotiropoulos GC, Prodromidou A, Kostakis ID, et al. Metaanalysis of laparoscopic vs open liver resection for hepatocellular carcinoma. Updates Surg,2017,69(3):291-311.
[23]Liu F, Li Q, Wei Y, et al. Laparoscopic versus open liver resection for difficult lesions: A metaanalysis. J Laparoendosc Adv Surg Tech A,2018,28(12):1428-1436.
[24]Wei F, Lu C, Cai L, et al. Can laparoscopic liver resection provide a favorable option for patients with large or multiple intrahepatic cholangiocarcinomas? Surg Endosc,2017,31(9):3646-3655.
[25]Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology,2020,76(2):182-188.
[26]Hayashi A, Misumi K, Shibahara J, et al. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am J Surg Pathol,2016,40(8):1021-1030.
[27]Sonbare DJ. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFCIHCC2009 Study Group. Ann Surg,2014,259(2):e36.
[28]Spolverato G, Yakoob MY, Kim Y, et al. The impact of surgical margin status on longterm outcome after resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol,2015,22(12):4020-4028.
[29]Li HJ, Wang Q, Yang ZL, et al. Laparoscopic versus open hepatectomy for intrahepatic cholangiocarcinoma: Systematic review and metaanalysis of propensity scorematched studies. Eur J Surg Oncol,2023,49(4):700-708.
[30]Kim BJ, Newhook TE, Tzeng CD, et al. Lymphadenectomy and marginnegative resection for biliary tract cancer surgery in the United States-Differential technical performance by approach. J Surg Oncol,2022,126(4):658-666.
[31]Belli A, Cioffi L, Russo G, et al. Liver resection for hepatocellular carcinoma in patients with portal hypertension: the role of laparoscopy. Hepatobiliary Surg Nutr,2015,4(6):417-421.
[32]Fuks D, Cauchy F, Ftériche S, et al. Laparoscopy decreases pulmonary complications in patients undergoing major liver resection: A propensity score analysis. Ann Surg,2016,263(2):353-361.
[33]Shirai D, Shinkawa H, Kabata D, et al. Laparoscopic liver resection reduces postoperative infection in patients with hepatocellular carcinoma: a propensity scorebased analysis. Surg Endosc,2022,36(12):9194-9203.
[34]Brustia R, Laurent A, Goumard C, et al. Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: Report of an international multicenter cohort study with propensity score matching. Surgery,2022,171(5):1290-1302.
[35]Shen Z, Tao L, Cai J, et al. Safety and feasibility of laparoscopic liver resection for intrahepatic cholangiocarcinoma: a propensity scorematched study. World J Surg Oncol,2023,21(1):126.

备注/Memo

备注/Memo:
基金项目：科技创新2030-“新一代人工智能”重大项目（2020AAA0105004）；北京大学第三医院临床队列建设项目（BYSYDL2023005）**通讯作者，Email：xiaofengling@bjmu.edu.cn（凌晓锋）；xiudianrong@163.com（修典荣）①病理科
更新日期/Last Update: 2024-10-06